Michael Higgins
Stock Analyst at Ladenburg Thalmann
(0.64)
# 3,734
Out of 4,711 analysts
24
Total ratings
30%
Success rate
-10.46%
Average return
Main Sectors:
Stocks Rated by Michael Higgins
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
MRNS Marinus Pharmaceuticals | Downgrades: Neutral | n/a | $0.23 | - | 2 | Aug 14, 2024 | |
VRDN Viridian Therapeutics | Downgrades: Neutral | n/a | $19.03 | - | 4 | May 9, 2024 | |
FBRX Forte Biosciences | Upgrades: Buy | $69 | $19.34 | +255.48% | 3 | Apr 8, 2024 | |
OVID Ovid Therapeutics | Reiterates: Buy | $7 | $1.00 | +600.63% | 1 | May 2, 2023 | |
SCYX SCYNEXIS | Reiterates: Buy | $15 | $1.00 | +1,400.15% | 1 | Apr 3, 2023 | |
ARTL Artelo Biosciences | Reiterates: Buy | $60 | $0.95 | +6,231.79% | 2 | Apr 3, 2023 | |
RYTM Rhythm Pharmaceuticals | Reiterates: Buy | $35 | $56.12 | -37.63% | 3 | Mar 2, 2023 | |
PTN Palatin Technologies | Maintains: Buy | $2 → $50 | $0.97 | +5,065.82% | 1 | Sep 9, 2022 | |
PHGE BiomX | Maintains: Buy | $130 → $80 | $0.62 | +12,803.23% | 2 | May 12, 2022 | |
NVAX Novavax | Downgrades: Sell | $105 | $8.70 | +1,106.90% | 2 | Aug 5, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $29 | $35.41 | -18.10% | 2 | Jan 4, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | n/a | $3.23 | - | 1 | Sep 27, 2017 |
Marinus Pharmaceuticals
Aug 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.23
Upside: -
Viridian Therapeutics
May 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $19.03
Upside: -
Forte Biosciences
Apr 8, 2024
Upgrades: Buy
Price Target: $69
Current: $19.34
Upside: +255.48%
Ovid Therapeutics
May 2, 2023
Reiterates: Buy
Price Target: $7
Current: $1.00
Upside: +600.63%
SCYNEXIS
Apr 3, 2023
Reiterates: Buy
Price Target: $15
Current: $1.00
Upside: +1,400.15%
Artelo Biosciences
Apr 3, 2023
Reiterates: Buy
Price Target: $60
Current: $0.95
Upside: +6,231.79%
Rhythm Pharmaceuticals
Mar 2, 2023
Reiterates: Buy
Price Target: $35
Current: $56.12
Upside: -37.63%
Palatin Technologies
Sep 9, 2022
Maintains: Buy
Price Target: $2 → $50
Current: $0.97
Upside: +5,065.82%
BiomX
May 12, 2022
Maintains: Buy
Price Target: $130 → $80
Current: $0.62
Upside: +12,803.23%
Novavax
Aug 5, 2020
Downgrades: Sell
Price Target: $105
Current: $8.70
Upside: +1,106.90%
Jan 4, 2019
Upgrades: Buy
Price Target: $29
Current: $35.41
Upside: -18.10%
Sep 27, 2017
Reinstates: Buy
Price Target: n/a
Current: $3.23
Upside: -